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volved in pathological conditions, it is inevitable to cause relevant side effects in healthy organs. In light of this,
a newprotein family, the chloride intracellular channels (CLICs), could be a promising class of therapeutic targets
for its intrinsic individualities: CLIC1 and CLIC4, in particular, not only are overexpressed in speciﬁc tumor types
or their corresponding stroma but also change localization and function from hydrophilic cytosolic to integral
transmembrane proteins as active ionic channels or signal transducers during cell cycle progression in certain
cases. These changes in intracellular localization, tissue compartments, and channel function, uniquely associated
with malignant transformation, may offer a unique target for cancer therapy, likely able to spare normal cells.
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Over the last two decades, an important role for ion channels in
tumor development and growth has been deﬁned. It is now clear that
an abnormal triggering of ion channel activity is important to support
the high rate of proliferation of tumor cells [1]. Most of the studies
have been focused on the role of potassium channels, but with the
ﬂow of time, chloride channels have gained a more prominent position
in carcinogenesis [2]. Chloride channels are ubiquitously expressed,
being localized both in plasmamembrane and in intracellular organelles
[3]. They have many different functions as the regulation of electrical
excitability, trans-epithelial ﬂuid transport, ion homeostasis, pH levels,
and cell volume regulation, the latter being particularly important for
cancer cells migration and inﬁltration [4–6]. These channels also partic-
ipate in the regulation of the cell cycle, probably as key factors in the
progression from G1 to S phase [7]. The pattern of chloride channel
properties and modulation has been extensively reviewed by several
authors describing voltage dependency, the possibility to be triggered
by calcium or activated by several ligands and second messengers, and
their primary role in cell volume regulation [8–12]. The different
families of chloride channels retain a heterogeneous regulation of
their activity, suggesting a multitask possibility of their participation
in the tumorigenesis process. There are multiple examples of chloride
channels participating in tumor development and progression, some
of which will be surveyed in the next paragraphs.
An emerging class of chloride ionic channels involved in cancer de-
velopment are the intracellular chloride channels (CLICs). So far, mem-
bers of this protein family have been identiﬁed in several cancer types
[13–34], but it is reasonable that, given their ubiquitous presence, CLIC
proteins will be found in most of the tumors. Several CLIC proteins are
overexpressed in cancer cells, and others are reduced when compared
to normal corresponding tissues. The peculiarity of CLICs, in particular
of CLIC1, is to be mainly present as a cytosolic protein in physiological
conditions and to be transiently expressed in the cell membrane during
stress conditions, like the increase of the oxidative levels of the cells [35]
undergoing rearrangement of the protein structure [36,37]. Thus, as the
three-dimensional conﬁguration of CLIC proteins change, they are able
to be functionally expressed as ion channels in themembrane. As an ex-
ample, cytoplasmic CLIC1 protein translocates to the plasmamembrane
as an ion channel during the tumorigenic processes [18,23] as well as in
other pathological conditions such as neurodegenerative disease pro-
gression [35,38]. In prolonged stress conditions, the functional expres-
sion and the membrane activity of CLIC1 is no longer transient but
becomes chronic and thus could represent a unique pharmacological
target [19].
Although most of our attention will be centered on the activity of
CLICs channel proteins during tumorigenesis, and in particular on the
functional role of CLIC1 and CLIC4 during cancer development, in the
next paragraphs, we will brieﬂy review the role of resident chloride
ionic channels in the tumorigenic process.
1.1. Voltage-gated chloride channels
ClC-3 is a member of the ClC chloride channels and transporters
family [10,12,39]. It has been suggested to be a molecular component
involved in activation of volume-sensitive Cl− currents [40] and to be
closely related to cell proliferation, migration, apoptosis, and acidiﬁca-
tion of synaptic vesicles [7]. Volume-activated chloride channels play
a crucial role in the process of regulatory volume decrease (RVD) in-
duced by hypotonic stresses. RVD is a phenomenon that contributes to
cell shape and volume changes required for cell migration, and so it
also has an important role in cancer progression [41]. Furthermore,
volume-regulated ion channels probably have a role in the angiogenic
process [42]. An increase in swelling activated chloride current and
ClC-3 expression has been observed in androgen-dependent prostate
cancer epithelial cells as a consequence of overexpression of Bcl-2 [43].Multiple studies focused on the role of ClC-3 in nasopharyngeal
carcinoma. In 2004, Mao and colleagues [44] showed that volume-
activated chloride current density in migrating human nasopharyngeal
carcinoma CNE-2Z cells was higher than in non-migrating cells. In 2008,
a positive correlation between the expression of ClC-3 and the rate of
cell migration was highlighted, being associated with an inhibition of
both volume-sensitive chloride currents and RVD when cells were
transfectedwith ClC-3 antisense oligonucleotides [45]. Later on, another
study revealed that ClC-3 down-regulation, by antisense treatment,
arrested CNE-2Z cells in the S phase. The authors speculated that the
expression of ClC-3 on intracellular vesicle membranes is necessary
for vesicular acidiﬁcation andmay be related to DNA synthesis allowing
the passage through the S restriction point [46]. Previously, Habela and
colleagues [47] found that the activity of the volume-activated chloride
channel is one of the important factors that regulate the passage of cells
through theG1 restriction point and that the Cl– current associatedwith
RVDplays an important role in cell proliferation. Regarding the relation-
ship between ClC-3 and the regulation of cell cycle in nasopharyngeal
carcinoma CNE-2Z cells, basal and volume-activated chloride currents
are increased by up-regulation of cyclin D1. Moreover, a direct interac-
tion between cyclin D1 and ClC-3 was detected by the ﬂuorescence
resonance energy transfer (FRET) technique [7].
In HeLa cells, a human cell line derived from cervical cancer, the in-
hibition of ClC-3 protein expression arrests cell cycle in the S phase;
from these experiments, it was concluded that volume-activated chlo-
ride channels play important roles in cell cycle-dependent migration
of HeLa cells [48].
ClC-3 and other ClC channels, especially ClC-2 and ClC-5, are partic-
ularly important in glioma cells [2,49]. These three channels are
expressed in glioma cell membranes, often associatedwith lamellipodia
[49]. Glioma cell invasion [50] and migration [51] involve a coordinated
reduction of cell volume. To achieve this state requires the activity of
both potassium and chloride channels and transporters [51,52]. ClCs,
in particular ClC-3, are the chloride channels involved in this operation.
However, the blockade of a single ClC is not sufﬁcient to reach a com-
plete inhibition of glioma cell invasion, suggesting a cooperative role
for these channels in the regulation of the volume of glioma cells [51,
53]. Exploiting the well-known activity of chlorotoxin (CTX), a blocker
of small conductance chloride channels, successful phase I/II clinical
trials for gliomas were reported using CTX-based bioconjugates [54].
1.2. Calcium-activated chloride channels
Although calcium-activated chloride channels (CaCCs) have been
studied in the last 30 years, they still have controversial molecular
identity. They play several important roles including epithelial secre-
tion, olfactory transduction,membrane excitability, regulation of vascu-
lar tone, and photoreception [55].
Calcium-activated chloride channel regulator 2 (CLCA2) is predomi-
nantly expressed in trachea and lungs [56]. It has been shown that loss
of CLCA2 expression in human breast cancer appears to be closely
associated with tumorigenicity [57] and that the expression of CLCA2
was down-regulated in colon cancer [58].
More recently, CLCA2 was shown to be strongly induced by p53 in
response to DNA damage, and the proposed mechanism to explain
its inhibitory effects on cell proliferation and survival was correlated
with its ability to acidify the cytosol [59]. These authors showed that
human CLCA2 enhances chloride current in breast cancer cells and re-
duces pH to 6.7. This observation is in agreement with the proposed
idea that some chloride channels are able to promote apoptosis by
reducing intracellular pH. Further studies on breast cancer demonstrat-
ed that the inactivation of CLCA2 also enhances the expression and
activation of focal adhesion kinase (FAK), a mechanism involved in
the inhibition in cancer cell migration and invasion [60].
Another member of calcium-activated chloride channels family is
anoctamin-1 (Ano1), a channel highly expressed in human interstitial
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onstrated that Ano1 is ubiquitously expressed in gastrointestinal stro-
mal tumors [62]. Since Ano1 is fundamental for proliferation of ICC
[63], it was proposed that it could play the same role in gastrointestinal
stromal tumor cells. Themechanism by which Ano1 regulates cells pro-
liferation was reported to be strictly correlated with chloride entry at
G1/S transition of the cell cycle. Recently, an increase in current density
of Ano1 channels in human prostate cancer cells has been described,
while the knockdown of ANO1 inhibits proliferation, invasion and, me-
tastasis of these cells, decreasing tumor growth. The authors claimed
that perturbed intracellular Ca2+ and Cl− ion concentrations and cell
volume are critical factors associated with androgen-independent
prostate cancer pathogenesis [64].
1.3. CFTR
CFTR is a chloride channel activated by cAMP-dependent phosphor-
ylation.Mutations of theCFTR gene affect the functioning of the channel,
leading to cysticﬁbrosis and congenital absence of the vas deferens. CFTR
is involved in multiple molecular pathways that modulate cell inﬂam-
mation and apoptotic signaling, so it is possible that mutations in this
gene could also modify the risk of development of cancer [65]. In
2010, McWilliams and colleagues [66] showed that patients carrying a
CFTR disease-associatedmutation display amodest increase risk of pan-
creatic cancer. In 2012, Peng and co-workers demonstrates that higher
CFTR expression is associated with cervical cancer progression, propos-
ing this channel as a novel tumor marker, prognostic indicator, and po-
tential therapeutic target [67]. No evidence regarding the molecular
mechanism by which the channel can be involved in cervical cancer
cells has been to date proposed. On the other hand, mutations in the
CFTR gene could also have a protective role in some tumors such as
lung cancer [68], melanoma, colon, and breast cancer [69]. Furthermore,
low expression of CFTRpolymorphismsmay contribute to a reduced risk
of prostate cancer [70].
2. The CLIC family
There are several ongoing clinical trials for different cancer types
having as target membrane resident chloride channels [71]. However,
all resident membrane chloride channels share the same archetype.
The increase of current density or protein levels in the membrane
does not represent per se a valid pharmacological target for antitumoral
approaches. Aswementioned before, the inhibition of these channel ac-
tivities could certainly interferewith tumor development but could also
cause malfunctioning of important physiological processes.
Conversely, we believe that a valid alternative could be represented
by some members of the CLIC family.
Among all the well-characterized chloride permeabilities, the
chloride intracellular channel (CLIC) protein family has been the last
discovered and still largely underexplored. These proteins are highly
conserved in all vertebrates suggesting their involvement in basic bio-
logical functions.
The ﬁrst identiﬁed intracellular chloride channel, p64, was isolated
from microsomes of bovine kidney and trachea and showed chloride-
selective channel function in lipid bilayers [72]. Distinct from mem-
brane resident ion channels, these proteins can exist both as cytoplas-
mic soluble proteins and as integral membrane elements with ion
channel activity. Membrane insertion occurs in response to different
stimuli from increases of cytoplasmic oxidation to pH changes [73–75].
CLIC1 and CLIC4 were the ﬁrst CLIC proteins to be cloned and func-
tionally studied [76,77], and so far they remain the most characterized
within thewhole family.While CLIC1was primarily identiﬁed in the nu-
clear membrane and then in the plasma membrane [76,78], CLIC4 sub-
cellular localization varieswith cell type being also localized to the inner
mitochondrial membrane [34,79], Golgi [80], and endoplasmic reticu-
lum [81]. Both channels are ubiquitously expressed with particularlyhigh levels in speciﬁc tissues and are overexpressed in several tumors
[13–34].
Although, as described in the previous paragraphs, chloride currents
often play an important role in cancer development and tumor cell
proliferation, the scenario highlighted for CLICs is peculiar. The cells
can indeed modulate the rate of translocation of the channels and its
functional insertion in the membranes as a consequence of perturba-
tions in their homeostasis. For example, it has been shown that CLIC1
and CLIC4 membrane insertion is redox regulated [35–37,82,83].
Our leading idea envisages CLIC proteins like second messengers
that can translocate to the cell membranes in response to modiﬁcation
of the basic cytoplasmic oxidative level. This mechanism can be tran-
sient or chronic according to the source and/or the time span of the
perturbation. In our view, transient CLIC membrane translocation
could be part of several physiological cell responses. On the contrary,
chronic CLIC functional expression in the cell membranes can lead to
severe pathological conditions and in particular to tumorigenic states
of the cell [84]. What is particularly interesting is that translocation in
response to external stimuli or internal changes in cell physiology may
be unique for each CLIC family member and cell type. For example,
redox changes in neuronal cells causes CLIC1 to migrate to the plasma
membrane [35,38], whereas a similar change in macrophages leads to
nuclear translocation of CLIC4 [85,86].
3. CLIC1 and CLIC4 in cancer
As the two channels have different patterns of expression in differ-
ent tissues, they also have different levels of expression in different
tumors. Moreover, it has been shown that the expression of CLIC4 tran-
script is regulated by p53 and tumor necrosis factorα (TNFα) and that it
is a direct response gene for both c-myc and p53, two mediators of
cancer pathogenesis in multiple tumor sites [34,87]. This regulation is
typical of CLIC4, and it has never been demonstrated for CLIC1. Thus, it
is likely that the functional roles of the two channels in tumor cells are
not superimposable and that their expression is regulated by different
pathways.
3.1. CLIC4 functional role in cancer
Multiple studies investigated the expression and the regulation of
CLIC4 in cancer cells. Suh and colleagues [33,88] suggested that CLIC4
reduction could be a novel target for tumor therapy since the expression
of CLIC4 antisensemRNA and the consequent reduction of CLIC4 protein
inhibits the growth of human osteosarcoma cells in vitro and in vivo, in-
creases apoptotic cells, and decreases cell proliferation. The antitumor
effect induced by CLIC4 down-regulation in sarcoma cells was enhanced
in combination with TNFα administration [89]. The speciﬁcity of CLIC4
in this response, however, was unclear as the antisense construct used
in the study also reduced CLIC1 and CLIC5 so that the loss of multiple
CLIC proteins may have contributed to the antitumor response.
A second study by this group clariﬁed the natural pattern of CLIC4
expression in multiple human epithelial cancers. Using in situmethods
on sections of human epithelial solid tumors, the study revealed that
the loss of CLIC4 is prevalent in tumor cells, and the gain of its expres-
sion in tumor stroma is a common trait of many human cancers and
marks malignant progression. The implication was that the reactivation
and restoration of CLIC4 in tumor cells or the reduction in tumor stromal
cells could provide a novel approach to inhibit tumor growth [89].
Progressing with these studies [26], the authors found that CLIC4 was
lost early in tumor evolution and reconstituting tumor cells with exog-
enous CLIC4 repressed tumor growth. Both in vitro studies on tumor cell
lines and in vivo experiments on tumor orthografts suggested that re-
constitution of tumor cells with CLIC4 re-established their responsive-
ness to TGF-β-mediated growth inhibition. Previously, it was reported
that CLIC4 is an integral part of TGF-β signaling and enhances TGF-β
responsiveness through its interference with dephosphorylation of
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implicated CLIC4 in the suppression of tumor cell growth and suggested
that its loss in tumor epithelium is a requirement for tumor progression.
Ronnov-Jessen and co-workers had ﬁrst suggested an important
function for CLIC4 in themyoﬁbroblast stroma of breast cancer patients
where it was the most up-regulated transcript after TGF-β treatment
[91]. Yao and colleagues [28] also explored TGF-ß1-induced ﬁbroblast-
to-myoﬁbroblast transdifferentiaton in ovarian cancer and concluded
that a ROS-CLIC4 up-regulated pathway is required in this process. In
a cutaneous cancer model, Shukla et al. [17] concluded that TGF-β
induced myoﬁbroblast conversion was mediated through activation of
p-38 by interfering with dephosphorylation of phospho-p38 in similar-
ity to its function on p-Smad activation. Further, these authors showed
that tumor orthografts would not grow on recipient mice lacking
CLIC4. A potential stromal function for CLIC4 is also suggested by its
important participation in angiogenesis where it is required for
endothelial tube formation through acidiﬁcation of vacuoles during
angioneogenesis [92]. Together, these studies indicate that drugs de-
signed to inhibit CLIC4 might have therapeutic potential by targeting
tumor stroma.
What we can conclude is that for now there are few hypotheses
about the biological mechanisms that can be the consequence of the
protein's regulation in diverse cancer cells. Moreover, all these studies
analyze the total level of CLIC4 proteinwithout distinguishing themem-
brane and the cytosolic fractions and thus its activity as a channel. In this
way, it is not known whether the modiﬁed level of expression of the
protein in these cells is also correlated with an alteration in the chloride
current. CLIC4 is a protein only recently discovered and studied, and so
there is still a long road to go to understand its role and themechanisms
that involve this protein in tumor generation and progression. More-
over, its intracellular distribution in the cellular organelles makes the
analysis of its membrane distribution challenging.
While the exact mechanisms by which CLIC4 functions as a tumor
suppressor or stromal activator are still open questions, increasing
evidence is accumulating showing that its expression and activity has
clinical relevance. Tumor proﬁling in bladder cancer [93], uterine
leiomyoma [94], glioma [95], andmelanoma [96] amongothers has doc-
umented signiﬁcant changes in CLIC4 expression during tumor forma-
tion. Proteome analysis revealed that CLIC4 is reduced in human
primary lung cancers and lung cancer cell lines, and the restoration of
CLIC4 in the cell lines inhibited growth [16]. CLIC4 expression was
reported to be a marker of colon cancer stem cells and associated with
a poor prognosis [15]. CLIC4 also enhanced MMP9 expression and inva-
sion in cancer cell lines escaping photodynamic therapy [97]. Of partic-
ular interest, high circulating CLIC4 was identiﬁed as a biomarker in
patients with ovarian cancer [19], and CLIC4 was present in exosomesFig. 1. CLIC4 expression inhibits growth of mouse and human squamous tumor
orthografts. (A) SP-1/F-Tet-On CLIC4-HA cells (doxycycline inducible CLIC4-HA) were
placed as orthografts on a prepared skin bed on nude mice, and mice were started on a
doxycycline diet at various times after grafting. Tumor measurements were made weekly
with calipers in three dimensions and recorded as volume. (B) Keratinocyteswere isolated
from wild type FVB/N or CMV-CLIC4-HA (FVB/N) transgenic mouse skin and transduced
with retrovirus encoding v-rasHa in culture. After 8 days in culture, cells were placed as
orthografts on nudemice and tumor size was measured weekly. (C) SCC-13 human squa-
mous cancer cells were placed subcutaneously on the ﬂank of nude mice. When tumors
were palpable at 4 weeks, adenoviruses encoding Beta-gal, native CLIC4 or nuclear
targeted CLIC4 were injected into the tumors at three sites each week. Tumors were mea-
sured weekly and reported as the fold increase in size relative to the starting size at week
4. Each group in grafting experiments consisted of 10 mice. Statistical evaluation used 2-
way ANOVA with Bonferroni post-test comparison. *p= 0.05, **p= 0.01, ***p= 0.001,
****p = 0.0001. (D) Six- to seven-week-old FVB/N single transgenic K5-rTA or K5-rTA-
Tet-O-CLIC4 double transgenic mice with doxycycline inducible CLIC4 targeted to the epi-
dermis by the keratin 5 (K5) promoter were initiated once with DMBA, placed on a doxy-
cycline diet 24 h later, and promoted with TPA for 20 weeks. Tumor multiplicity was
monitored each week for 30 weeks. Each group consisted of 6 mice and error bars are
SEM. Because of the small number of mice in the study, statistical signiﬁcance could not
be achieved. One mouse with tumors in the CLIC4 group expired at week 20. Reprinted
with permission of Oxford University Press from Suh et al. CLIC4 is a tumor suppressor
for cutaneous squamous cell cancer. Carcinogenesis 33:986-995, 2012.
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lating exosomes in ovarian cancer patients is directly related to disease
progression [100]. Thus, in addition to an important function in cancer
pathogenesis, CLIC4 is immerging as a potential biomarker to monitor
tumor progression and recurrence in multiple human cancers.
The loss of CLIC4 in tumor epithelium is particularly worthy of
note in squamous tumors of the esophagus [101] and cervix (Yuspa
et al., unpublished data). To model this, CLIC4 was examined in
squamous cancer development on mouse skin [26]. During progres-
sion from benign to malignant tumors induced on mouse skin by
dimethylbenz(a)anthracene (DMBA) followed by multiple applications
of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA),
the expression of CLIC4 is diminished in tumor epithelium. This is
paralleled by loss of CLIC4 protein in mouse and human tumor cell
lines as they progress from benign to malignant in vitro.
Soluble CLIC4 translocates from the cytoplasm to the nucleus under
cell stress conditions such as DNA damage, senescence, or metabolic
stress fromdrugs [102]. Transduction of keratinocyteswith an oncogen-
ic mutant of HRAS is an early event required for skin tumor induction.
Remarkably, associated with the earliest signs of HRAS-induced trans-
formation, the translocation of CLIC4 to the nucleus in response to
DNA damage is prevented. Since nuclear CLIC4 is required for its ability
to enhance TGF-β signaling, the absence of CLIC4 in the nucleus could
interfere with the growth inhibition in response to TGF-β common to
many tumor cells. In fact, reconstituting nuclear CLIC4 via adenovirus
transduction restored TGF-β-mediated growth inhibition to tumorFig. 2. Native chloride currents in stem/progenitor cells from four different human glioblastom
forated patches of CSCs isolated from four different patient postsurgical specimens of grade IV g
perfusedwith bath solution to record the total current of the cell (top traces). Successively, ioni
IAA94+200 μMDIDS (Cl− channels inhibitor that does not affect CLIC1 current). By analytical su
we obtained the IAA94-sensitive current (middle traces); the DIDS-sensitive current was calcu
effect (bottom traces). (E–H) Current/voltage relationships from the data in panels A–D, resp
IAA94-sensitive current (red squares) and DIDS-sensitive current (green circle) (Angelini, M.,cells. Mechanistically, it had been shown that nuclear translocation of
CLIC4 occurred in response to S-nitrosylation of a critical cysteine to
expose a nuclear localization signal [85]. By using auranoﬁn to block
thioredoxin reductase and restoring a nitrosylating environment in
tumor cells, nuclear translocation of CLIC4 is restored. The importance
of CLIC4 in tumor cell growth was emphasized in a number of in vivo
studies of tumor orthografts (Fig. 1). Under multiple conditions in
which CLIC4 expression can be elevated in tumor grafts, tumor growth
is inhibited. Furthermore, in transgenic mice in which CLIC4 is ex-
pressed to high levels in the epidermis, tumor induction by DMBA/
TPA is inhibited. These data suggest that CLIC4 in tumor cells is a
tumor suppressor and understanding the mechanism of repression of
CLIC4 in squamous tumors is a priority for potential therapy.3.2. CLIC1 functional role in cancer
Concerning CLIC1 and its expression in cancers, CLIC1 protein levels
are reportedly increased in human breast ductal carcinoma [103],
gastric cancer [31], gallbladder metastasis [104], colorectal cancer [29],
nasopharyngeal carcinoma [105], ovarian cancer [106], hepatocellular
carcinoma[107], and high-grade gliomas [22]. All these analyses pro-
pose CLIC1 as a tumormarker, sometimes detectable even in the plasma
of patients and so very useful in the clinic. In 2004, Huang proposed that
the overexpression of CLIC1 in liver cancer might alter cell division rate
and/or antiapoptosis signaling, resulting in cellular transformation.as (GBMs). (A–D) Representative ionic currents (total, IAA94 and DIDS current) from per-
lioblastoma: hGBM#9 (A), hGBM#10 (B), hGBM#18 (C), hGBM#7 (D). Cells were initially
c currents were recorded during perfusion of 100 μM IAA94 (CLIC1 inhibitors) and 100 μM
btraction of the ionic current after 100 μMIAA94 addition from the total current of the cell,
lated by subtracting the current after 200 μM DIDS addition from the current after IAA94
ectively. Total current (blue diamond) is plotted together with the current amplitude of
Savalli, N. and Mazzanti, M. unpublished results).
Fig. 3. Positive correlation between the relative abundance of CLIC1-mediated current and
glioblastoma aggressiveness. Averages of the ratio of IAA94-sensitive currents (A) or
DIDS-sensitive currents (B) over the total current of the same cell, in stem/progenitor
cells isolated from hGBM#9 (pink, n= 6), hGBM#10 (blue, n= 15), hGBM#18 (green,
n=12), and hGBM#7 (orange, n=6). (C) The 3D plot correlating the relative abundance
of CLIC1-mediated current (IIAA94/IDIDS), the membrane potential, and the tumor aggres-
siveness (deﬁned as the latency of tumor formation occurring after inoculation of CSCs
in nude mice). For example, at 0 mV, the IIAA94/IDIDS ratio was 0.5 ± 0.12 (n = 6) in
hGBM#9 cells, 1.54 ± 0.35 (n = 15) in hGBM#10 cells, 1.74 ± 0.09 (n = 6) in
hGBM#18 cells, and 2.32 ± 0.42 (n = 12) in hGBM#7 cells. In the tumors analyzed in
this study, the average survival of nude mice inoculated with CSCs was 152 ± 2 days for
hGBM#9, 128 ± 2 days for hGBM#10, 88 ± 4 days for hGBM#18, and 55 ± 4 days for
hGBM#7. Note that the more aggressive is the glioblastoma, the more CLIC1-mediated
current is represented compared to the other Cl− currents in the cells. (Angelini, M.,
Savalli, N. and Mazzanti, M. unpublished results).
2528 M. Peretti et al. / Biochimica et Biophysica Acta 1848 (2015) 2523–2531In mouse hepatocarcinoma cells, CLIC1 is overexpressed [108,109]
and contributes to promoting migration and invasion. Surprisingly, the
down-regulation of CLIC1 enhanced proliferative activity, increased
the ratio of cells entering G2/M phase, and decreased percentage of
apoptosis [108]. This is in accord with previous studies [110] in which
treatment with CLIC1 blocker IAA94 led to arrest of CHO-K1 cells in
the G2/M stage of the cell cycle. These results indicate that CLIC1 is a
critical factor in the development of lymphatic metastasis but that fur-
ther investigations are still needed to explore themolecularmechanism
in tumor occurrence and development.
Two recent studies [14,23] on the function of CLIC1 in LOVO cells, a
human colon adenocarcinoma cell line characterized by a highmetasta-
tic potential, suggested that CLIC1 expression is related to themetastatic
potential of colon cancer cells.Moreover, they analyzed the role of CLIC1
as an ion channel by suppressing its current with IAA94 or knocking-
down CLIC1 expression. In both cases, migration and invasion of colon
cancer cells were inhibited, an effect attributed to a decrease in RVD
(regulatory volume decrease) capacity. The relationship between
CLIC1 and ROS levels in LOVO cells has also been studied [14]. The inhi-
bition of CLIC1 channel activity by IAA94 reduces the intracellular ROS
production during the hypoxia-reoxygenation treatment, leading to
decreased cell migration. CLIC1 and ROS cross-talk can possibly be in-
volved also in other tumors since an alteration in the oxidative state of
the cell is typical of cancer cells, and it has been shown by our group
that not only CLIC1 translocation is regulated by ROS but also that
CLIC1 chloride current is necessary to support ROS production by
NADPH oxidase [35]. It is known that changes in ROS levels are fun-
damental for the progression of the cell cycle [111,112]. One hypoth-
esis is that ROS increase could regulate CLIC1membrane insertion or,
conversely, the boost of CLIC1 chloride current could sustain ROS
production necessary for the progression through the cell cycle.
The possibility to regulate the insertion of a channel in the plasma
membrane in response to speciﬁc signals and to have an increasing
pool of cytoplasmatic proteins ready to undergo structural modiﬁca-
tions and membrane insertion could be very useful for tumor devel-
opment that is characterized by a high rate of proliferation and
migration.
An important role for CLIC1 as a chloride channel is speciﬁcally asso-
ciated with the development of glioblastoma (GBM), the most aggres-
sive and frequent brain tumor. In these tumors the bulk of malignant
cells is generated by a rare fraction of self-renewing, multipotent cancer
stem cells (CSCs) responsible for tumor origin, progression, and recur-
rence [113,114]. These subpopulations of cells have shown intrinsic re-
sistance to therapy, being then capable to repopulate the tumor after
surgical or chemotherapeutic treatment [115]. CLIC1 is highly expressed
in glioblastoma and bothmRNA and protein levels are increased in high
grade in comparison to low grade brain tumors or control (non-tumor)
brain tissue [18,22]. Upon CLIC1 silencing, both proliferative capacity
and self-renewal properties in vitrowere impaired.Moreover, immuno-
deﬁcient mice injected into the nucleus caudatus with CLIC1-silenced
CSCs, survived longer than non-treated CSCs-injected control mice
[18]. However, RNA interference experiments per se are not able to dis-
tinguish whether CLIC1 is active as a cytoplasmic component or if the
ability tomodulate CSCs proliferation andmigration is due to its plasma
membrane ion channel property. To address this speciﬁc task, Setti and
co-workers [18] showed not only that the IAA94-sensitive membrane
current was drastically reduced in CLIC1 silenced human glioma CSCs
but also that CSC neurospheres, treated for 48 h with NH2-CLIC1 anti-
body, active as a CLIC1 channel blocker only from outside the cell [78],
compromised cancer development in injected mice. In recent unpub-
lished experiments, Angelini and colleagues calculated the ratio be-
tween CLIC1-mediated current (IIAA94) and other Cl− currents (IDIDS)
obtained from perforated-patch experiments in CSCs isolated from
four different human glioblastoma postsurgical specimens (Fig. 2). The
relative large amount of CLIC1-mediated current positively correlates
with tumor aggressiveness as shown in Fig. 3.
2529M. Peretti et al. / Biochimica et Biophysica Acta 1848 (2015) 2523–2531These results support the idea that the abundance of CLIC1 protein in
theplasmamembrane is a precise sign of a cell in unbalanced physiolog-
ical condition. This condition could be a transient event in a regular
function of the cell life. However, if the protein overexpression becomes
chronic as in glioblastoma CSCs, CLIC1 activity could be instrumental to
the progress of the pathological state. More important, if the modulato-
ry action is represented by the chloride ion channel, CLIC1 could be
considered a privileged therapeutic target for CSCs in glioblastoma as
well as in other untreatable tumors.
A recent report strongly supported this hypothesis showing that
CLIC1 activity can be pharmacologically regulated, discriminating
among CSCs and normal stem cells. It was indeed shown that metfor-
min, an antidiabetic drug able to affect CSC viability [116], is a powerful
inhibitor of CLIC1 conductance [117]. Importantly, this effect was evi-
dent only in glioblastoma CSC-enriched cultures, while umbilical cord-
derived mesenchymal stem cells (MSC) were unaffected. The differen-
tial inhibitory effects of metformin on CLIC1 activity in CSCs and MSCs
closely correlated with the drug-induced reduction of cell viability
that was observed in the tumor cells but not in normal stem cells
[117]. Moreover, in light of the proposed role of over-activation of
CLIC1 in glioblastoma cells due to its sustained membrane localization,
in MSCs that are not sensitive to the antiproliferative effects of metfor-
min, CLIC1 wasmainly conﬁned to a cytosolic localization in an inactive
form not reachable by metformin [117]. These results strongly support
the potential role of CLIC1 as a pharmacological target that allows the
discrimination between normal and tumor cells.
4. Conclusion and remarks
Ionic channels have always been considered extremely valid
pharmacological targets. Since they are involved in crucial physiological
mechanisms, malfunctioning membrane ionic permeabilities are
known to be responsible for several pathological states. The CLIC protein
family, even in its peculiar expression, should be incorporated into this
protein class. The dimorphic nature of CLIC proteins offers the possibil-
ity to be involved in cellular functions as cytoplasmic reagents or as
membrane ion conducting elements as well-documented by the two
examples reported above.
Understanding the involvement of CLIC family proteins in health and
disease is still in a developing state. There are evident technical and
conceptual difﬁculties slowing down our ability to understand the
functional role of CLIC proteins in the biology of the cell. The close se-
quence and structural homology among the familymembers confounds
the interpretation of the results. Furthermore, the different three-
dimensional structures acquired by the individual proteins could be
seen as an obstacle to separate CLIC cytoplasmic and membrane func-
tions. However, the discovery of speciﬁc inhibitors, in particular confor-
mation antibodies, not only for individual family members but also for
the different protein conformations would have a strong impact in the
ﬁeld. The next step of the research should concentrate our efforts to
uncover if there is a functional continuity between the cytoplasmic
and the membrane form of the protein and determine if the two pro-
tein conformations are active and localized in the different cell
environments depending on the cell state. The identiﬁcation of
conformation-speciﬁc pharmacological inhibitors and/or regulators
of CLIC protein activities could open novel and more efﬁcient ways
for cancer treatment.
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